Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Focus on ziprasidone.

B Green1

  • 1Halton Hospital and the University of Liverpool, Liverpool, UK. bengreen@liverpool.ac.uk

Current Medical Research and Opinion
|January 5, 2002
PubMed
Summary
This summary is machine-generated.

Ziprasidone, an antipsychotic, effectively treats schizophrenia and schizoaffective disorder by targeting dopamine and serotonin receptors. It offers benefits for negative and depressive symptoms with fewer side effects than older medications.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Post-traumatic stress disorder cases reported by UK occupational physicians 1996-2024.

Occupational medicine (Oxford, England)·2026
Same author

Spinal Epidural Abscess Without Fever: Challenging the Classic Triad.

Irish medical journal·2024
Same author

Comparison of the survival of different isolates of SARS-CoV-2 in evaporating aerosols.

Aerosol science and technology : the journal of the American Association for Aerosol Research·2023
Same author

Pulse- and field-resolved THz-diagnostics at 4 <sup></sup> generation lightsources.

Optics express·2019
Same author

Clinical relevance of non-tuberculous mycobacteria isolated from respiratory specimens: seven year experience in a UK hospital.

Scientific reports·2019
Same author

On-chip THz spectrometer for bunch compression fingerprinting at fourth-generation light sources.

Journal of synchrotron radiation·2018
Same journal

Multidrug-resistant <i>Pseudomonas aeruginosa</i> in Jordan: epidemiology, trends, determinants, and clinical outcomes.

Current medical research and opinion·2026
Same journal

RSV disease and vaccination knowledge, attitudes, and practices among US adults: a 2024-2025 RSV season survey.

Current medical research and opinion·2026
Same journal

Clinical and healthcare resource utilization outcomes following revision knee arthroplasty with and without a gradually reducing radius revision knee system.

Current medical research and opinion·2026
Same journal

Medication adherence measurement methods and their reported relationship with medication safety outcomes: a scoping review.

Current medical research and opinion·2026
Same journal

BMI response to dapagliflozin with or without semaglutide across obesity classes: a real-world observational study conducted in Saudi Arabia.

Current medical research and opinion·2026
Same journal

Comparative efficacy of tislelizumab + FOLFOX or CAPOX for gastric/gastroesophageal junction adenocarcinoma: an exploratory matching-adjusted indirect comparison.

Current medical research and opinion·2026
See all related articles

Area of Science:

  • Pharmacology
  • Neuroscience
  • Psychiatry

Background:

  • Ziprasidone is a novel antipsychotic agent.
  • It exhibits combined dopamine and serotonin receptor antagonist activity.
  • Conventional antipsychotics have limitations in treating negative and affective symptoms.

Purpose of the Study:

  • To evaluate the efficacy and safety of ziprasidone.
  • To determine the effective dosage range for ziprasidone.
  • To compare ziprasidone's profile with conventional antipsychotics.

Main Methods:

  • Clinical trials were conducted to assess ziprasidone's effects.
  • Dosage range explored was 80-160 mg/day.
  • Adverse effects and symptom improvements were monitored.

Related Experiment Videos

Main Results:

  • Ziprasidone demonstrated efficacy in schizophrenia and schizoaffective disorder.
  • Positive, negative, and depressive symptoms showed improvement.
  • Common adverse effects included somnolence (14%) and nausea (10%).
  • Ziprasidone showed comparable efficacy to conventional antipsychotics with fewer side effects.
  • Cognitive effects were less pronounced compared to conventional agents.

Conclusions:

  • Ziprasidone is an effective antipsychotic with a favorable side-effect profile.
  • Its combined receptor activity offers benefits for a broader range of schizophrenia symptoms.
  • Ziprasidone represents a valuable addition to the available antipsychotic treatments.